The 13th International AIDS Society Conference on HIV Science (IAS 2025)
13 July - 17 July, 2025, Rwanda
Treatment with emtricitabine/tenofovir alafenamide (F/TAF) and cobicistat-boosted atazanavir (ATV/c) or darunavir (DRV/c) maintained high rates of virologic suppression through 48 weeks in children living with HIV, based on two cohorts of the GS-US-216-0128 study presented at IAS 2025.
